What the studies show
Mild-to-moderate gastrointestinal symptoms in 81% (3.6 mg) and 90% (6.0 mg) versus 48% on placebo in SYNCHRONIZE-1, with substantial discontinuation.
Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.
- 1Survodutide in adults with obesity: SYNCHRONIZE-1, a randomised, double-blind, placebo-controlled phase 3 trial.N Engl J Med, published online 7 June 2026725 adults, 76 weeks, 3.6 mg and 6.0 mg versus placebo.
In context
Survodutide is a once-weekly peptide that activates both the GLP-1 and glucagon receptors. In SYNCHRONIZE-1, a 725-person phase 3 trial published in June 2026, it produced 12–13% weight loss at 76 weeks against 5% on placebo, with gastrointestinal symptoms in up to 90% of participants. Its distinctive result is in the liver: a phase 2 trial resolved MASH without worsening fibrosis in 83% of patients at the top dose. It is not approved anywhere.
Survodutide is investigational. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Survodutide proven to cause GI side effects?
What studies are behind the grade?
Is Survodutide approved for this?
Other outcomes for Survodutide
- BBody weight1 phase 3 RCT + phase 2
- BLiver disease (MASH resolution)1 phase 2 RCT; phase 3 running
- BLiver fat and visceral fatPhase 3 (SYNCHRONIZE-MASLD)
- BHeart rate increaseadversePhase 2 + 3
Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →